- Home
- ARVN vs KMDA Comparison
ARVN vs KMDA Comparison
Compare ARVN & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- KMDA
- Stock Information
- Founded
- ARVN 2015
- KMDA 1990
- Country
- ARVN United States
- KMDA Israel
- Employees
- ARVN N/A
- KMDA N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- ARVN Health Care
- KMDA Health Care
- Exchange
- ARVN Nasdaq
- KMDA Nasdaq
- Market Cap
- ARVN 456.2M
- KMDA 410.6M
- IPO Year
- ARVN 2018
- KMDA N/A
- Fundamental
- Price
- ARVN $7.61
- KMDA $6.90
- Analyst Decision
- ARVN Buy
- KMDA Strong Buy
- Analyst Count
- ARVN 22
- KMDA 2
- Target Price
- ARVN $20.02
- KMDA $13.00
- AVG Volume (30 Days)
- ARVN 1.3M
- KMDA 50.0K
- Earning Date
- ARVN 10-29-2025
- KMDA 11-12-2025
- Dividend Yield
- ARVN N/A
- KMDA 2.90%
- EPS Growth
- ARVN N/A
- KMDA 27.97
- EPS
- ARVN N/A
- KMDA 0.32
- Revenue
- ARVN $372,800,000.00
- KMDA $169,517,000.00
- Revenue This Year
- ARVN $1.61
- KMDA $14.49
- Revenue Next Year
- ARVN N/A
- KMDA $10.12
- P/E Ratio
- ARVN N/A
- KMDA $20.92
- Revenue Growth
- ARVN 299.57
- KMDA 9.67
- 52 Week Low
- ARVN $5.90
- KMDA $5.17
- 52 Week High
- ARVN $29.61
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- ARVN 49.90
- KMDA 42.54
- Support Level
- ARVN $7.58
- KMDA $6.80
- Resistance Level
- ARVN $7.89
- KMDA $7.15
- Average True Range (ATR)
- ARVN 0.37
- KMDA 0.20
- MACD
- ARVN -0.03
- KMDA -0.00
- Stochastic Oscillator
- ARVN 18.42
- KMDA 15.87
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.